Lee Dong Hyun, Han Jung Woo, Hahn Seung Min, Kim Byung Moon, Lyu Chuhl Joo, Lee Sung Chul, Kim Dong Joon, Lee Christopher Seungkyu
Department of Ophthalmology, Inha University School of Medicine, 27, Inhang-ro, Jung-gu, Incheon 22332, Korea.
Department of Ophthalmology, Yonsei University College of Medicine, 50-1, Yonseiro, Seodaemun-gu, Seoul 03722, Korea.
J Clin Med. 2021 Nov 20;10(22):5421. doi: 10.3390/jcm10225421.
(1) Background: To analyze changes in treatment patterns for advanced retinoblastoma over time and differences in globe salvage rates; (2) Methods: Retrospective, observational case-control study of 97 eyes of 91 patients with advanced retinoblastoma (Group D and E).; (3) Results: Patients were divided into two groups based on whether they were treated before or after intraarterial chemotherapy (IAC) was introduced in our center in 2010. Before 2010, primary treatment pattern was enucleation, which was performed in 57.6% of cases, whereas primary treatment pattern after 2010 was IAC combined with intravenous chemotherapy (IVC), which was performed in 78.1%. Intravitreal chemotherapy (IVitC) has been performed to treat vitreous and subretinal seeding since 2015. The 5-year globe salvage rate of IVC alone was 24.0% for Group D and 0% for Group E, whereas that of IVC-IAC was 50.4% for Group D and 49.7% for Group E. Whether IVitC was performed or not did not significantly contribute to globe salvage rate. There was one metastatic death in the IVC alone group.; (4) Conclusions: Primary treatment pattern changed from enucleation to IAC-based treatment, which can now save nearly half of eyes with advanced retinoblastoma with excellent safety profile and survival rate.
(1) 背景:分析晚期视网膜母细胞瘤治疗模式随时间的变化以及眼球挽救率的差异;(2) 方法:对91例晚期视网膜母细胞瘤患者(D组和E组)的97只眼进行回顾性观察性病例对照研究;(3) 结果:根据患者在2010年我院引入动脉内化疗(IAC)之前或之后接受治疗,将患者分为两组。2010年之前,主要治疗模式是眼球摘除术,57.6%的病例采用该方法,而2010年之后主要治疗模式是IAC联合静脉化疗(IVC),78.1%的病例采用该方法。自2015年起采用玻璃体内化疗(IVitC)治疗玻璃体和视网膜下种植。单独IVC治疗时,D组5年眼球挽救率为24.0%,E组为0%;IVC-IAC治疗时,D组5年眼球挽救率为50.4%,E组为49.7%。是否进行IVitC对眼球挽救率无显著影响。单独IVC组有1例发生转移死亡;(4) 结论:主要治疗模式从眼球摘除术转变为以IAC为基础的治疗,目前该治疗可挽救近一半的晚期视网膜母细胞瘤患眼,安全性和生存率良好。